Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results

Rockwell Medical, Inc. (NASDAQ: RMTI), a leading provider in the dialysis industry, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company delivered a performance that offers important insights for shareholders and potential investors, with several key metrics and strategic updates that may be price sensitive and influence share values.

Key Financial Highlights

• Net Sales:
  • Q4 2025: \$18.3 million
  • Full-Year 2025: \$69.3 million (within previously guided range of \$65.0M to \$70.0M)
• Gross Margin:
  • Year-End 2025: 17% (up from 10% in 2024, and in line with guidance of 16% to 18%)
• Net Income (Loss):
  • Q4 2025: Net loss of \$0.8 million
  • Full-Year 2025: Net loss of \$0.5 million, a significant improvement from 2024’s net loss of \$8.4 million
• Adjusted EBITDA:
  • Q4 2025: \$0.4 million
  • Full-Year 2025: \$0.4 million (compared to guidance of (\$0.5M) to \$0.5M)
• Cash and Cash Equivalents & Investments Available-for-Sale:
  • \$25.0 million as of December 31, 2025 (up from \$21.6 million a year earlier)
• Shares Outstanding:
  • Common shares: 39,405,302
  • Common stock and equivalents: 49,945,902

2025 Performance Review

• The company delivered on its 2025 guidance for net sales, gross margin, and Adjusted EBITDA, reflecting improved operational execution and cost control initiatives.
• Gross margin expansion from 10% to 17% year-over-year demonstrates significant operational efficiency improvements.
• Net loss narrowed dramatically, and Adjusted EBITDA turned positive, indicating the company is approaching sustainable profitability.

2026 Guidance and Strategic Outlook

• 2026 Adjusted EBITDA Guidance: \$1 million to \$2 million, highlighting a focus on continued profitability improvements.
• The company aims to drive sustainable, profitable growth in 2026 by:
  • Acquiring new customers and renewing contracts with existing customers
  • Improving price and product mix
  • Boosting operational efficiencies
  • Selectively expanding its portfolio through disciplined partnerships and business development
• Management emphasizes its intention to build on recent momentum, diversify the portfolio, and further enhance profitability.

Non-GAAP Financial Measures

The company uses Adjusted EBITDA as a key metric, defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other non-recurring items.

Other Noteworthy Information for Shareholders

• Balance Sheet: Strong liquidity position with nearly \$25 million in cash and equivalents.
• Shareholder Equity: \$32.6 million as of year-end 2025.
• Risks and Forward-Looking Statements: The company’s forward-looking statements, including 2026 guidance, are subject to risks and uncertainties, including market acceptance, operational execution, and macroeconomic factors as outlined in SEC filings.

Potential Price Sensitive Information

• Return to profitability is within reach for 2026 based on guidance and 2025’s positive Adjusted EBITDA.
• Gross margin expansion and cost controls are contributing to improved financial performance.
• The company’s strategic initiatives in customer growth, pricing, and operational efficiency could further boost revenues and profits, potentially increasing shareholder value.
• Any future contract wins, business development activity, or operational risks could meaningfully impact the company’s financial trajectory and share price.

Disclosure of Exhibit

• The full press release containing the earnings results is available as Exhibit 99.1 to the Form 8-K and can be referenced for more granular details.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties and actual results may differ materially. Investors should review the company’s SEC filings and consider their investment objectives and risk tolerance before making investment decisions.

View ROCKWELL MEDICAL, INC. Historical chart here